Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report

BACKGROUND: Dabigatran is a direct thrombin inhibitor with a favorable effectiveness and safety profile when compared to vitamin K antagonists, both in randomized trials and real world registries of atrial fibrillation patients. Yet, physicians’ fear of high bleeding risk scenarios in daily clinical...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Thromb J
Main Authors: Tralhão, António, Aguiar, Carlos, Ferreira, Jorge, Rebocho, Maria José, Santos, Emília, Martins, Dinis, Neves, José Pedro
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5583973/
https://ncbi.nlm.nih.gov/pubmed/28878572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-017-0147-z
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki